Solésence, Inc. reported a decline in revenue for the third quarter of 2025, with total revenue reaching $14.6 million, down from $16.9 million in the same period of 2024. However, the company experienced an increase in revenue for the nine months ended September 30, 2025, totaling $49.6 million compared to $39.8 million for the same period in 2024. The decrease in quarterly revenue was attributed to lower sales in the personal care ingredients and advanced materials categories, which was partially offset by increased sales in consumer products. The company’s product revenue for the third quarter was $14.5 million, down from $16.8 million year-over-year, while for the nine-month period, it increased to $49.4 million from $39.5 million.
In terms of profitability, Solésence reported a net loss of $1.1 million for the third quarter of 2025, compared to a net income of $3.0 million in the same quarter of 2024. For the nine-month period, the company recorded a net income of $1.6 million, down from $4.8 million in the prior year. The increase in operating expenses, particularly in selling, general, and administrative costs, which rose to $3.1 million from $1.9 million year-over-year, contributed to the net loss. The company also noted an increase in research and development expenses, reflecting its commitment to innovation and product development.
Operationally, Solésence has seen significant changes, including a strategic rebranding from Nanophase Technologies Corporation to Solésence, Inc. in March 2025, and its subsequent uplisting to Nasdaq under the ticker symbol SLSN in April 2025. The company continues to focus on its core markets in skin health and beauty, leveraging its proprietary technologies to enhance product performance. As of September 30, 2025, Solésence reported a total of 70.5 million shares outstanding, with an accumulated deficit of $98.8 million.
The company’s customer base remains concentrated, with three significant customers accounting for approximately 60% of total revenue in the third quarter of 2025. Solésence has also expanded its international sales, generating $1.7 million in revenue from overseas markets during the third quarter, compared to $735,000 in the same period of 2024. The company is actively working to enhance its manufacturing capabilities and improve operational efficiencies to better meet growing demand for its consumer products.
Looking ahead, Solésence anticipates continued growth driven by its focus on consumer products and the development of innovative solutions in skin health. The company plans to invest in expanding its manufacturing capacity and enhancing its product offerings, while also navigating challenges related to inflation and supply chain dynamics. Management remains optimistic about the future, citing strong demand for its proprietary technologies and products as key drivers of growth in the coming years.
About SOLESENCE, INC.
Solesence, Inc. (formerly Nanophase Technologies) specializes in scientifically-driven skin health and beauty solutions, including proprietary active pharmaceutical ingredients (APIs) and fully formulated consumer products. The company develops mineral-based UV protection, environmental defense, and aesthetic skincare products for prestige and mass markets. Its core value lies in innovative nanotechnology, formulation expertise, and a vertically integrated business model serving global brand partners.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.